Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Polycystic Ovary Syndrome 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Insulin Resistance 1Inflammation 1Hyperandrogenism 1Anovulation 1

Interventions

fludarabine phosphate 43Whole-Body Irradiation 36Mycophenolic Acid 36Peripheral Blood Stem Cell Transplantation 31Cyclophosphamide 31Tacrolimus 28Busulfan 22Antilymphocyte Serum 21Cyclosporine 19fludarabine 17ruxolitinib 16Melphalan 16Methotrexate 15Cytarabine 12thymoglobulin 9Sirolimus 9Etoposide 9Granulocyte Colony-Stimulating Factor 8Filgrastim 8Cyclosporins 8Radiotherapy 7Cord Blood Stem Cell Transplantation 7Rituximab 6Alemtuzumab 6merphos 5Stem Cell Transplantation 5Flow Cytometry 5Azacitidine 5sargramostim 4ponatinib 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Myeloproliferative Disorders × salicylsalicylic acid × Clear all
NCT04146038 2023-05-24

Salsalate, Venetoclax, and Decitabine or Azacitidine for the Treatment of Acute Myeloid Leukemia or Advanced Myelodysplasia/Myeloproliferative Disease

Rutgers, The State University of New Jersey

Phase 2 Completed
5 enrolled 9 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡